Gradual escalation over 16-20 weeks
In December 2025, Eli Lilly announced topline results from the phase-3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of retatrutide in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity
Step 2 Review and eligibility A medical provider will look over your form and determine if youre a good fit for treatmentno appointment required
The pharmaceutical firm said a weekly 2.4-milligram dose of semaglutidethe generic name for both Wegovy and Ozempicresulted in a 20% reduction in heart attacks and strokes, following a five-year trial that involved over 17,600 participants aged 45 or older
Clinical studies have shown that patients can lose a significant percentage of their body weight over several months when using Semaglutide alongside lifestyle adjustments
The best outcomes usually combine internal antioxidant support (IV) with external skincare and professional skin therapies